Business Context and Reporting Period
This Form 8-K Current Report from TherapeuticsMD, Inc. (Nasdaq: TXMD) covers events occurring on June 1, 2020. The filing primarily addresses significant changes in executive leadership, specifically the appointment of a new Chief Financial Officer (CFO) and the retirement of the incumbent.
Key Financial Metrics and Compensation
This filing does not report operational financial metrics such as revenue, profit, cash flow, or debt levels. Instead, it details the financial terms of the new CFO's employment agreement:
- Base Salary: $420,000 annually.
- Target Bonus: 75% of base salary ($315,000), with the 2020 bonus not prorated.
- Equity Grants:
- 651,500 Restricted Stock Units (RSUs) vesting in equal annual installments over three years.
- 151,500 Performance Share Units (PSUs) contingent on the Company achieving quarterly EBITDA breakeven by the quarter ending December 31, 2022.
- Severance: Up to 12 to 18 months of base salary plus bonus acceleration under specific termination scenarios.
- Outgoing CFO Compensation: Daniel A. Cartwright will receive a consulting agreement with aggregate payments of $200,000 over a term of not less than three years.
Material Changes
The primary material change reported is the transition of the Chief Financial Officer role:
- Appointment: James C. D'Arecca became CFO effective June 1, 2020. He previously served as Senior Vice President and Chief Accounting Officer at Allergan plc.
- Departure: Daniel A. Cartwright retired as CFO effective June 1, 2020. He will remain with the company in a transitional capacity and as a consultant.
Outlook, Risks, and Contingencies
Performance Contingency: A significant portion of the new CFO's equity compensation (151,500 PSUs) is contingent on the Company achieving quarterly EBITDA breakeven no later than the quarter ending December 31, 2022. Failure to meet this target results in forfeiture of these units.
Restrictive Covenants: The new CFO is subject to a non-compete agreement for 18 months (extendable to 24 months) and a non-solicitation agreement for 24 months post-employment.
Management Commentary: The filing notes Mr. D'Arecca's extensive background in pharmaceutical finance, including roles at Allergan, Bausch & Lomb, Merck, and PricewaterhouseCoopers.
Investor Verification Checklist
- Verify the vesting schedule and fair value of the 651,500 RSUs and 151,500 PSUs granted to the new CFO.
- Confirm the Company's current EBITDA trajectory to assess the likelihood of meeting the December 2022 breakeven target required for PSU vesting.
- Review the upcoming Form 10-Q for the quarter ending June 30, 2020, which will contain the full text of the Employment Agreement as an exhibit.
- Monitor the transition period to ensure continuity in financial reporting and internal controls during the CFO changeover.